[Current pharmacotherapy of Parkinson's disease].
Parkinson's disease (PD) is one of the most common neurodegenerative disorders. The morbidity is about 1-2 of 1000 under 65 years, but it increases to 1-2 of 100 in the population over 65 years. PD became the model of degenerative disorders either concerning the etiopathogenesis or the therapeutic possibilities. Recently the therapy is focused mostly on pharmaceutics, although the treatment of PD is complex. The new drugs improve the quality of life, and there is some evidence that some of them may slow down the progression of the disease. These drugs may provide a neuroprotective therapy, and so a better life expectancy.
Takáts
A
A
Altalános Orvostudományi Kar, Neurológiai Klinika, Semmelweis Egyetem, Budapest.
D000975:Antioxidants / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D018450:Disease Progression; D018491:Dopamine Agonists / Q000627:therapeutic use; D006801:Humans; D008017:Life Expectancy; D010300:Parkinson Disease / Q000188:drug therapy*; D011788:Quality of Life
D000975:Antioxidants; D000978:Antiparkinson Agents; D018680:Cholinergic Antagonists; D018491:Dopamine Agonists